Moderna stock plunges 18% after company lowers 2025 sales forecast by $1 billion
1. Moderna lowered 2025 sales guidance by $1 billion due to uncertainties. 2. Projected 2025 revenue now between $1.5 billion and $2.5 billion. 3. Market share for Covid shots dropped to 40% in 2024 from 48%. 4. Vaccination rates fell 7% in the U.S. compared to 2023. 5. Moderna plans 10 new product approvals in next three years.